Amgen Inc. (AMGN) Stock Analysis
Amgen Inc. (NASDAQ: AMGN) is one of the world's largest independent biotechnology companies, discovering and manufacturing human therapeutics across oncology, cardiovascular disease, inflammation, bone health, and rare diseases. Investors research Amgen for its established product portfolio, consistent dividend payments, and exposure to aging-population healthcare trends.
Get a full AI research report on AMGN
6-step deep analysis in ~90 seconds. Quick research is free — no signup.
What does Amgen Inc. do?
Amgen generates revenue by discovering, developing, manufacturing, and commercializing biologic drugs—primarily monoclonal antibodies and recombinant proteins. Its portfolio includes blockbuster franchises like Enbrel (rheumatoid arthritis), Repatha (cardiovascular), Prolia (osteoporosis), and KYPROLIS (multiple myeloma), which collectively serve millions of patients globally. The company operates a capital-intensive model requiring significant R&D investment, but mature products generate substantial cash flow to fund pipeline development and shareholder returns.
Bull case
- ✓Established blockbuster portfolio with Enbrel, Repatha, and Prolia generating recurring revenue from chronic-disease patients with high treatment persistence.
- ✓Forward P/E ratio of 18.1 is below the trailing P/E of 26.4, suggesting market expectations for earnings growth as newer products mature and pipeline candidates advance.
- ✓Gross margin of 71.9% and operating margin of 35.5% demonstrate pricing power and operational leverage typical of successful biopharmaceutical companies.
- ✓Dividend yield of 2.37% with a payout ratio of 60.9% indicates sustainable shareholder distributions backed by free cash flow generation.
- ✓Diversified therapeutic pipeline spanning oncology, immunology, and rare diseases reduces dependence on any single product or indication.
Bear case
- ✗Patent expirations on key drugs like Enbrel (2023 in some markets) and Prolia create revenue headwinds and require successful new product launches to offset losses.
- ✗High debt-to-equity ratio of 490.3% reflects substantial leverage; refinancing risk and interest expense could pressure profitability in a rising-rate environment.
- ✗PEG ratio of 2.18 suggests the stock may be priced at a premium relative to expected earnings growth, leaving limited margin of safety for growth disappointments.
- ✗Regulatory and reimbursement pressures in major markets (US, EU) continue to constrain pricing and market access for specialty pharmaceuticals.
- ✗Quick ratio of 0.95 indicates tight near-term liquidity relative to current liabilities, though this is common in capital-intensive industries with predictable cash flows.
AMGN valuation & financial health
Amgen trades at a trailing P/E of 26.4 with a forward P/E of 18.1, indicating the market is pricing in meaningful earnings growth ahead. The company's ROE of 91.5% and ROA of 8.7% reflect efficient capital deployment, though the high ROE is partly a function of the elevated leverage (debt-to-equity of 490%). With a net margin of 23.0% and gross margin of 71.9%, Amgen demonstrates strong profitability and pricing power. The current ratio of 1.37 and quick ratio of 0.95 suggest adequate liquidity, though the company relies on operational cash generation. The PEG ratio of 2.18 implies the valuation may be pricing in growth expectations that warrant monitoring against actual pipeline progress.
The bottom line
Amgen presents a classic large-cap biotech profile: mature, profitable operations with a strong dividend, offset by patent cliff risks and high leverage. Key factors to weigh include the execution risk on pipeline candidates to replace expiring revenues, the sustainability of current pricing in an increasingly cost-conscious healthcare environment, and the company's ability to service debt while funding R&D. Investors should monitor upcoming clinical trial results, regulatory decisions on pipeline assets, and quarterly earnings trends to assess whether the forward P/E discount reflects genuine value or unpriced execution risk.
Frequently asked questions
What does Amgen Inc. do?
Amgen discovers, develops, manufactures, and sells biologic drugs—primarily monoclonal antibodies and recombinant proteins—for treating cancer, cardiovascular disease, inflammation, bone disorders, and rare diseases. The company operates globally and serves millions of patients through established products and an active clinical pipeline.
Is AMGN a dividend stock?
Yes, Amgen pays a dividend with a current yield of 2.37% and a payout ratio of 60.9%, indicating the company distributes a material portion of earnings to shareholders while retaining capital for R&D and debt service. The dividend has historically been raised annually.
Is AMGN overvalued or undervalued?
The stock's trailing P/E of 26.4 is elevated, but the forward P/E of 18.1 suggests the market expects earnings growth. Whether this represents fair value depends on the probability of pipeline success, patent cliff mitigation, and pricing sustainability—factors that require ongoing monitoring of clinical and regulatory developments.
What are Amgen's biggest products?
Amgen's leading franchises include Enbrel (rheumatoid arthritis and psoriasis), Repatha (cardiovascular risk reduction), Prolia (osteoporosis), KYPROLIS (multiple myeloma), and XGEVA (skeletal complications). These products collectively represent a significant portion of revenue and serve chronic-disease populations with high treatment adherence.
What are the main risks for AMGN investors?
Key risks include patent expirations on blockbuster drugs, high debt levels (debt-to-equity of 490%), regulatory and reimbursement pressures on drug pricing, and pipeline execution risk. Additionally, biosimilar competition and healthcare cost-containment initiatives in major markets could pressure margins.
How does Amgen compare to other biotech companies?
Amgen is one of the largest independent biotechnology companies by market capitalization, with a more mature, diversified product portfolio and higher profitability margins than many peers. However, it carries higher leverage than some competitors and faces similar patent cliff and pricing pressures affecting the broader industry.
Research AMGN with AI in seconds
Company profile, financials, events, competition, risks and synthesis — automated.
Start free — no signupFor informational purposes only — not investment advice. Analysis is AI-generated from public data and may contain errors. Always do your own research.